X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Acuitas’ Lipid Nanoparticle (LNP) technology will support Bayer’s in vivo gene editing and protein replacement programs with the goal of specifically delivering RNA payloads to the desired target organ, the liver.
Lead Product(s): Undisclosed
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Bayer AG
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 06, 2023
Details:
As part of the agreement, the companies will combine the optimized delivery of Acuitas' highly validated LNP technology with Arbor’s differentiated, proprietary CRISPR gene editing technology designed for use in vivo in patients with rare liver diseases.
Lead Product(s): LNP-based Gene Therapy
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Cell and Gene therapy
Recipient: Arbor Biotechnologies, Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 25, 2022
Details:
Through this agreement, Myeloid de-risks the development of its candidates by leveraging Acuitas’ science and proven regulatory, to rapidly translate Myeloid’s innovation to patients. The MT-301 and MT-302 programs will utilize Acuitas’ LNP deliver technology.
Lead Product(s): MT-301
Therapeutic Area: Oncology Product Name: MT-301
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Myeloid Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 19, 2022
Details:
Under the terms of the agreement, GC Biopharma will obtain the option to license Acuitas’ LNP technology for up to four undisclosed targets, on a non-exclusive basis, for vaccine or therapeutic development.
Lead Product(s): mRNA Vaccine
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Vaccine
Partner/Sponsor/Collaborator: GC Biopharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 28, 2022
Details:
Investments will harness the power of the mRNA-LNP technology and deliver potential new breakthrough vaccines and therapeutics that address significant unmet needs for patients. This agreement expands LNP capabilities and explore more projects within existing vaccines area.
Lead Product(s): mRNA-LNP Based Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 10, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
